WO2010025577A3 - Zubereitung zur prävention und/oder behandlung und/oder verhinderung der weiterverbreitung von atemwegserkrankungen - Google Patents

Zubereitung zur prävention und/oder behandlung und/oder verhinderung der weiterverbreitung von atemwegserkrankungen Download PDF

Info

Publication number
WO2010025577A3
WO2010025577A3 PCT/CH2009/000299 CH2009000299W WO2010025577A3 WO 2010025577 A3 WO2010025577 A3 WO 2010025577A3 CH 2009000299 W CH2009000299 W CH 2009000299W WO 2010025577 A3 WO2010025577 A3 WO 2010025577A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
nasal
spreading
avoiding
treating
Prior art date
Application number
PCT/CH2009/000299
Other languages
English (en)
French (fr)
Other versions
WO2010025577A2 (de
Inventor
Roland Schoop
Blerim Krasniqi
Silvia Bommer
Andreas Suter
Martin Tobler
Original Assignee
Bioforce Ag Roggwil Tg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH01431/08A external-priority patent/CH699653B1/de
Application filed by Bioforce Ag Roggwil Tg filed Critical Bioforce Ag Roggwil Tg
Publication of WO2010025577A2 publication Critical patent/WO2010025577A2/de
Publication of WO2010025577A3 publication Critical patent/WO2010025577A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die vorliegende Erfindung betrifft eine Zubereitung zur Prävention und/oder Behandlung und/oder Verhinderung der Weiterverbreitung von Atemwegserkrankungen, welche durch Viren induziert werden und von bakteriellen Infektionen begleitet sein können, welche dadurch gekennzeichnet ist, dass diese Zubereitung als aktive Komponente einen Extrakt aus wenigstens einer Echinacea Art oder deren Subspecies enthält, und dass diese Zubereitung entweder - in einer solchen Form vorliegt, welche zur Inhalation und/oder für die pulmonale und/oder nasale und/oder buccale und/oder okulare und/oder parenterale, insbesondere die intravenöse oder subkutane, Verabreichung geeignet ist, oder - in einer solchen Form vorliegt, welche die Viren am Eindringen in den menschlichen und/oder tierischen Körper hindert, mit der Massgabe, dass die nasale Verabreichung dieser Zubereitung in der Form von Nasentropfen, Nasensprays, Dosierungssprays und Nasensalben zur Behandlung von Virusinfektionen des Nasen-Rachen-Raumes ausgenommen ist.
PCT/CH2009/000299 2008-09-08 2009-09-07 Zubereitung zur prävention und/oder behandlung und/oder verhinderung der weiterverbreitung von atemwegserkrankungen WO2010025577A2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH01431/08A CH699653B1 (de) 2008-09-08 2008-09-08 Zubereitung zur Prävention und/oder Behandlung und/oder Verhinderung der Weiterverbreitung von Atemwegserkrankungen.
CH1431/08 2008-09-08
CH01053/09A CH699471B1 (de) 2008-09-08 2009-07-07 Zubereitung zur Prävention und/oder Behandlung und/oder Verhinderung der Weiterverbreitung von Atemwegserkrankungen.
CH1053/09 2009-07-07

Publications (2)

Publication Number Publication Date
WO2010025577A2 WO2010025577A2 (de) 2010-03-11
WO2010025577A3 true WO2010025577A3 (de) 2010-07-29

Family

ID=41797573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2009/000299 WO2010025577A2 (de) 2008-09-08 2009-09-07 Zubereitung zur prävention und/oder behandlung und/oder verhinderung der weiterverbreitung von atemwegserkrankungen

Country Status (2)

Country Link
CH (1) CH699471B1 (de)
WO (1) WO2010025577A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022122175A1 (en) 2020-12-11 2022-06-16 Herb-Pharma Ag Antiviral composition comprising cistus and medical device for its administration
CH719229A1 (de) * 2021-12-09 2023-06-15 A Vogel Ag Zusammensetzung zur Prävention und/oder Behandlung und/oder Eindämmung der Weiterverbreitung viraler Zoonosen, inklusive SARS-CoV-2 und deren Varianten.
GR1010387B (el) * 2022-02-28 2023-01-25 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", Συνδυασμος φυτικων εκχυλισματων με αντι-ιικη δραση με εμφαση στους ιους της γριπης η1ν1 και η3ν2

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4438589A1 (de) * 1994-10-28 1995-03-23 Reingard Dr Muenster Nasentherapeutikum
US20020048551A1 (en) * 1999-04-06 2002-04-25 Keller Brian C. Delivery of biologically active material in a liposomal formulation for administration into the mouth
WO2006118459A1 (en) * 2005-04-29 2006-11-09 Campina Nederland Holding B.V. Antiviral peptides
RU2309762C1 (ru) * 2006-03-28 2007-11-10 Государственное научное учреждение Научно-исследовательский ветеринарный институт Нечерноземной зоны РФ Российской академии сельскохозяйственных наук Способ профилактики респираторных болезней телят
WO2007144676A2 (en) * 2006-06-13 2007-12-21 Freund Tamas Use of echinacea or preparations thereof in compositions for the treatment of anxiety

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4438589A1 (de) * 1994-10-28 1995-03-23 Reingard Dr Muenster Nasentherapeutikum
US20020048551A1 (en) * 1999-04-06 2002-04-25 Keller Brian C. Delivery of biologically active material in a liposomal formulation for administration into the mouth
WO2006118459A1 (en) * 2005-04-29 2006-11-09 Campina Nederland Holding B.V. Antiviral peptides
RU2309762C1 (ru) * 2006-03-28 2007-11-10 Государственное научное учреждение Научно-исследовательский ветеринарный институт Нечерноземной зоны РФ Российской академии сельскохозяйственных наук Способ профилактики респираторных болезней телят
WO2007144676A2 (en) * 2006-06-13 2007-12-21 Freund Tamas Use of echinacea or preparations thereof in compositions for the treatment of anxiety

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BODINET CORNELIA ET AL: "Effect of oral application of an immunomodulating plant extract on influenza virus type A infection in mice.", PLANTA MEDICA, vol. 68, no. 10, October 2002 (2002-10-01), pages 896 - 900, XP002583063, ISSN: 0032-0943 *
DATABASE WPI Week 200780, Derwent World Patents Index; AN 2007-869407, XP002583061 *
GUIOTTO P ET AL: "Pharmacokinetics and immunomodulatory effects of phytotherapeutic lozenges (bonbons) with Echinacea purpurea extract", PHYTOMEDICINE, GUSTAV FISCHER VERLAG, STUTTGART LNKD- DOI:10.1016/J.PHYMED.2008.05.003, vol. 15, no. 8, 1 August 2008 (2008-08-01), pages 547 - 554, XP022819237, ISSN: 0944-7113, [retrieved on 20080625] *
PLESCHKA S ET AL: "Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian Influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV)", VIROLOGY JOURNAL 2009 BIOMED CENTRAL LTD. GBR LNKD- DOI:10.1186/1743-422X-6-197, vol. 6, 2009, XP002583064, ISSN: 1743-422X *
WOELKART KARIN ET AL: "Pharmacokinetics of the main alkamides after administration of three different Echinacea purpurea preparations in humans", PLANTA MEDICA, vol. 74, no. 6, May 2008 (2008-05-01), pages 651 - 656, XP002583062, ISSN: 0032-0943 *

Also Published As

Publication number Publication date
CH699471A2 (de) 2010-03-15
WO2010025577A2 (de) 2010-03-11
CH699471B1 (de) 2010-05-14

Similar Documents

Publication Publication Date Title
WO2011000566A3 (en) Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
WO2009129470A3 (en) Methods for treating herpes virus infections
WO2011111966A3 (en) Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
WO2006050489A3 (en) Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP3042910A3 (de) 2'-spiro-nukleoside zur therapie von hepatitis c
ZA201108892B (en) Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
WO2011158039A8 (en) Ureido-pyrazole derivatives for use in the treatment of respiratory syncitial virus (rsv) infection
WO2010120524A3 (en) Methods of modulating an immune response to a viral infection
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
WO2007057763A3 (en) Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
MX2015012397A (es) Composiciones y metodos basados en anticuerpos neutralizados suministrados intranasalmente para eficacia terapeutica aumentada.
WO2012093258A3 (en) Irf5- related treatment and screening
WO2007089945A3 (en) Treating diseases by targeting silt3
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2009094191A3 (en) Methods of treating viral infections
WO2013048153A3 (ko) 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
WO2013059559A3 (en) Compounds and methods for enhancing innate immune responses
CA2862755A1 (en) Antiviral compounds with a dibenzooxaheterocycle moiety
WO2007029041A3 (en) Interferon lambda therapy for treatment of respiratory diseases
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
WO2013058484A3 (ko) 인제난 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
WO2013036610A3 (en) Compositions comprising mg53 and methods for the treatment and prevention of airway injury

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09775786

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09775786

Country of ref document: EP

Kind code of ref document: A2